Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus ORGARAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus ORGARAN.
LIQUAEMIN LOCK FLUSH vs ORGARAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Danaparoid is a low molecular weight heparinoid that exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) through binding to antithrombin III and heparin cofactor II.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
Adults: Initial intravenous bolus of 2500 IU (anti-Xa), followed by continuous intravenous infusion of 400 IU/h for 2 hours, then 300 IU/h for 2 hours, then 200 IU/h for 5 days; or subcutaneous injection of 750 IU twice daily. Dose adjusted to maintain anti-Xa levels of 0.5-1.0 IU/mL.
None Documented
None Documented
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Terminal elimination half-life: 18-25 hours (mean ~19 hours) in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe renal failure, CrCl <30 mL/min).
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Renal: 40-50% as unchanged drug; biliary/fecal: minimal; small amount metabolized via desulfation and N-acetylation.
Category C
Category C
Anticoagulant
Anticoagulant